NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $15.54 +0.37 (+2.41%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Adaptive Biotechnologies Stock (NASDAQ:ADPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADPT alerts:Sign Up Key Stats Today's Range$15.21▼$15.9450-Day Range$10.91▼$15.6552-Week Range$4.27▼$15.94Volume1.09 million shsAverage Volume2.02 million shsMarket Capitalization$2.37 billionP/E RatioN/ADividend YieldN/APrice Target$13.56Consensus RatingModerate Buy Company Overview Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development. The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners. Adaptive also develops T-cell receptor (TCR) discovery services to support the discovery and development of novel TCR-based therapeutics. Its offerings span research services, clinical diagnostics, and collaborative programs with leading drug developers to advance immune-driven medicine. Founded in 2009 and headquartered in Seattle, Washington, Adaptive Biotechnologies maintains research and operations facilities in North America and Europe. The company collaborates with global technology and life sciences organizations, including a strategic partnership with Microsoft to apply machine learning to immune data. Adaptive’s platform has been utilized in oncology, autoimmune and infectious disease research across multiple continents. Adaptive Biotechnologies is led by co-founder and CEO Chad Robins, under whose guidance the firm continues to expand its molecular profiling capabilities and build a world-class immune medicine business.AI Generated. May Contain Errors. Read More Adaptive Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreADPT MarketRank™: Adaptive Biotechnologies scored higher than 59% of companies evaluated by MarketBeat, and ranked 468th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Downside RiskAdaptive Biotechnologies has a consensus price target of $13.56, representing about 12.7% downside from its current price of $15.52.Amount of Analyst CoverageAdaptive Biotechnologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adaptive Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.92) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -18.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -18.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 11.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.13% of the outstanding shares of Adaptive Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 10.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.79 Percentage of Shares Shorted6.13% of the outstanding shares of Adaptive Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 10.79%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.82 News SentimentAdaptive Biotechnologies has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Adaptive Biotechnologies this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADPT Stock News HeadlinesAdaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade)October 6, 2025 | seekingalpha.comGuggenheim Begins Coverage on Adaptive Biotechnologies (NASDAQ:ADPT)October 2, 2025 | americanbankingnews.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.October 13 at 2:00 AM | Priority Gold (Ad)A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 AnalystsOctober 1, 2025 | benzinga.comGuggenheim starts Adaptive with Buy on cancer test leadershipSeptember 30, 2025 | msn.comAdaptive Biotechnologies initiated with a Buy at GuggenheimSeptember 30, 2025 | msn.comThe Bull Case For Adaptive Biotechnologies (ADPT) Could Change Following Analyst Upgraded Earnings OutlookSeptember 29, 2025 | finance.yahoo.comAdaptive Biotechnologies (ADPT): Exploring Valuation After Recent Share Price MomentumSeptember 27, 2025 | uk.finance.yahoo.comSee More Headlines ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $5.99 on January 1st, 2025. Since then, ADPT stock has increased by 159.1% and is now trading at $15.5220. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Corporation (NASDAQ:ADPT) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.07. The business's revenue for the quarter was up 36.3% compared to the same quarter last year. Read the conference call transcript. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Top institutional shareholders of Adaptive Biotechnologies include Voya Investment Management LLC (0.86%), Assenagon Asset Management S.A. (0.03%) and Sound Income Strategies LLC. Insiders that own company stock include Chad M Robins, Harlan S Robins, Julie Rubinstein, Tycho Peterson, Francis Lo, Kyle Piskel, Nitin Sood, Peter M Neupert, R Mark Adams, Stacy L Taylor, Robert Hershberg and Michelle Renee Griffin. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/05/2025Today10/13/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADPT CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees790Year Founded2009Price Target and Rating Average Price Target for Adaptive Biotechnologies$13.22 High Price Target$20.00 Low Price Target$9.00 Potential Upside/Downside-12.8%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$159.49 million Net Margins-59.07% Pretax Margin-59.08% Return on Equity-60.93% Return on Assets-23.03% Debt Debt-to-Equity RatioN/A Current Ratio2.84 Quick Ratio2.75 Sales & Book Value Annual Sales$205.22 million Price / Sales11.26 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book11.07Miscellaneous Outstanding Shares152,274,000Free Float142,528,000Market Cap$2.31 billion OptionableOptionable Beta2.06 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ADPT) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.